Cover Image
市場調查報告書

嗜酸性細胞增多症:開發中產品分析

Hypereosinophilic Syndrome - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361633
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
嗜酸性細胞增多症:開發中產品分析 Hypereosinophilic Syndrome - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 54 Pages
簡介

嗜酸性細胞增多症(HES)是原因不明,持續6個月以上末梢血中成熟的嗜酸性粒細胞計數升高(≥1500嗜酸性粒細胞/mm³),而由於嗜酸性粒細胞的擴大而造成心臟,神經系統或骨髓等部位產生障礙的疾病。HES要排除克隆嗜酸性粒細胞增多(如白血病)和反應性嗜酸性粒細胞增多(感染疾病和自體免疫疾病,特異反應性,腎上腺功能降低症,熱帶性嗜酸性粒細胞增加症,癌症等)下才能確診。

本報告提供嗜酸性細胞增多症治療藥的開發情形相關調查,提供開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

嗜酸性細胞增多症概要

治療藥的開發

  • 開發中產品概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

嗜酸性細胞增多症治療藥的開發企業

  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • Knopp Biosciences LLC
  • Kyowa Hakko Kirin
  • Stemline Therapeutics, Inc.

嗜酸性細胞增多症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9324IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H1 2017, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.

The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Phase II stages are 1 and 4 respectively.

Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypereosinophilic Syndrome - Overview
    • Hypereosinophilic Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hypereosinophilic Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline Plc
    • Knopp Biosciences LLC
    • Kyowa Hakko Kirin Co Ltd
    • Stemline Therapeutics Inc
  • Hypereosinophilic Syndrome - Drug Profiles
    • benralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexpramipexole dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mepolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypereosinophilic Syndrome - Dormant Projects
  • Hypereosinophilic Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Mar 31, 2017: GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
      • Mar 21, 2017: Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers
      • Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials
      • Jan 04, 2017: Knopp Biosciences Receives Key Patent Directed to Treatment for Hypereosinophilic Syndromes, Asthma, and Other Eosinophilic Diseases
      • Dec 14, 2016: Steroid-Sparing Effects of Dexpramipexole in Hypereosinophilic Syndromes (HES) Reported at American Society of Hematology 2016 Annual Meeting
      • Mar 13, 2014: Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole
      • Jan 08, 2014: Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hypereosinophilic Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H1 2017
  • Hypereosinophilic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Hypereosinophilic Syndrome - Pipeline by Stemline Therapeutics Inc, H1 2017
  • Hypereosinophilic Syndrome - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Hypereosinophilic Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top